Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Revolution Medicines (RVMD) secured FDA approval for Rasonque just one month after filing, marking one of the fastest approvals for a novel pancreatic cancer therapy. The RAS inhibitor demonstrated strong Phase 3 trial results, and analysts are projecting peak annual sales of $11.5 billion for the drug.

RVMD shares have surged 178% year-to-date on the approval and commercial potential. The company is positioning Rasonque for expansion beyond pancreatic cancer into other indications, targeting RAS mutations that affect approximately 30% of solid tumors. This broader addressable market underpins the aggressive sales forecast.

The biotech now faces the challenge of commercial execution after the sharp rally. At current levels, investors are pricing in significant market share capture across multiple oncology indications. The $11.5 billion peak sales estimate would place Rasonque among the top-tier cancer franchises, competing with established players including LLY, JNJ, and ABBV in the oncology space.